Covid-19 roundup: Pfizer hustling up millions of doses of vaccine — details $748M BioNTech deal; CDC tweaks stance on controversial malaria drugs
Pfizer and BioNTech are ready to outline the details of their ambitious alliance on a Covid-19 mRNA vaccine for the world.
Their plan now is to start human trials in a matter of days, while ramping up manufacturing for a global market well ahead of the first readout. And the German mRNA company — largely owned by the billionaire Struengmann brothers — is getting a big upfront to go with the collaboration.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.